Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hyper-diluted Botox for Mid-Face Skin Quality
NCT03097835Phase 2Completed
- Sponsor
- Steve Yoelin M.D. Medical Associates
- Start
- Feb 2018
- Primary completion
- Jul 2018
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of botulinum toxin type A, sponsored by Steve Yoelin M.D. Medical Associates. Primary endpoint: Percent Improvement in Skin Quality at 135 days. Started Feb 2018; status: completed.
02
Drugs
botulinum toxin type A
Beyond the preview
Go deeper on NCT03097835.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03097835.